US Stem Cell Inc (USRM)

[Dragon Lady]

LOL ANOTHER PR just full of "if's" and "maybes" and "when this, then maybe that" and "we'll let you know at some future date" (you know, like the MIRROR trial that never went anywhere, kinda like that?), and "probably might happen soon if and when all this other stuff probably happens" same old, same old IMO.

http://finance.yahoo.com/news/bioheart-updates-diversifies-clinical-development-150000986.html

Man, they're gonna try and run it on PR hype again IMO. Classic BHRT from my watching this one.

I've probably never read a PR so full of holes and "what ifs " and "maybes" and whatever- just trying desperately to move their stock and nothing more IMO. Another classic PR for the history books to me.

Man, how many words and what it really says to me is nothing conclusive- not one thing that will happen for certain or has happened. Normally, PR is to say WHAT HAS HAPPENED and is a DONE DEAL, not a bunch of "what could maybe probably we hope to happen" hype. OTC-ville classics IMO.

Best line IMO, is the "will be given at a FUTURE DATE". Well SHAZAM, there ya have it. They've been saying they'll update these trials "at a future date" for FIVE YEARS NOW (see the recent SEC filings). Notice this PR, NOTHING concrete about funding. Nothing. Only "we'll let you know at a FUTURE DATE". You know what a "future date" means in legal-eze? Anytime between now and FOREVER is a "future date". Wow, we'll "let you know" so sit tight and hang on and hope for the ole "future date" to arrive SOMEDAY maybe. Wow. Amazing use of the ole PR machine IMO. Amazing.

Notice too- the MUCH HYPED ole MIRROR "phase 3" is DEAD. It never happened. How bout a revisit of those PR "claims" and hype- that helped run the stock back then, and now it's DONE, OVER after "one patient enrolled", remember that one?

http://www.marketwired.com/press-release/bioheart-announces-phase-iii-mirror-trial-for-myocell-initiated-otcqb-bhrt-1807938.htm

"The MIRROR trial is fully funded by Bioheart and will be conducted at up to 35 centers in North and South America. The trial is designed to enroll up to 126 patients over a 12 month time period. "

So it was FULLY FUNDED but was never really "funded" and never actually took place??? How exactly does that work? Exactly how, I'm confused I think- like really confused? So it again was FULLY FUNDED as of that PR, but then is not cancelled and never really happened per today's PR, but we're to believe that all this "new stuff maybe" in today's PR is going to now be "funded" and "happen someday" and blah, blah, blah? OK, I guess? But where's the explanation of how MIRROR "unfunded itself" and actually NEVER HAPPENED- where is that all explained in great detail in this wonderful PR. Where can we read all about that being explained? The PR made vast claims- and now they NEVER HAPPENED?? How's that possible? Was the MIRROR PR's as originally put out then never true in the first place? How is that possible?

" The first patient has been enrolled in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). "

From the PR, dated todat Jan 29, 2015- look at all the "maybes" and all the "what ifs" and "future date maybes" and nothing about FUNDING in this one:

"Bioheart will advance its Myocell(TM) and Myocell(TM) SDF-1 programs forward for the treatment of chronic heart failure. The Myocell(TM) product candidate (known as the MARVEL clinical trial) will advance into US FDA phase 3 clinical evaluation for the treatment of chronic heart failure. The re-start of the Myocell(TM) clinical trial is conditional to re-engagement with the principle investigators and related institutional requirements and internal preparations. Additional information on the timing of patient enrollment will be given at a future date. The Company estimates that Myocell(TM) for the treatment of chronic heart failure could achieve market approval in 2019. Bioheart also plans to advance its Myocell(TM) SDF-1 program (known as the REGEN clinical trial), a second generation product, for the treatment of chronic heart failure forward. The Company is currently seeking a joint development partner to collaborate with the development of the Myocell(TM) SDF-1 program. A joint development partner may, among many attributes, augment the Bioheart research, development and clinical team, bring unique expertise, intellectual property and capabilities to the program, share program costs, accelerate the program to approval and accelerate potential market penetration. The company estimates that Myocell(TM) SDF-1 for the treatment of chronic heart failure could achieve market approval in 2021. According to the American Heart Association, about 4.9 million Americans are living with congestive heart failure. Of these, 2.5 million Americans are males and 2.4 million are females. Ten of every 1,000 people over age 65 have this condition. There are about 400,000 new cases each year. According to the US Center for Disease Control, cardiovascular disease and strokes account for an estimated $432 billion in healthcare and related costs. If approved by the US FDA, the Company believes that Myocell(TM) and Myocell(TM) SDF-1 could significantly improve the cardiovascular health of chronic heart failure patients and reduce the associated cost of treating these patients.

Also in the cardiovascular space, Bioheart plans to advance an Adipocell(TM) based product candidate forward for the treatment of Critical Limb Ischemia (CLI). Company sponsored investigator lead research in the treatment of CLI has produced positive outcomes. The development of CLI usually involves multiple sites of arterial obstruction that severely reduce blood flow to the tissues. CLI manifests itself clinically as rest pain, non-healing wounds or tissue necrosis. Severe cases of CLI can result in amputations. The Sage Group reported that an estimated 2 million people in the US have CLI and reflecting the aging population, this number is projected to grow to almost $2.8 million by 2020. The Company believes that with a device regulatory approach for Adipocell(TM), market approval could be achieved by 2017 for the treatment of CLI.

The Company has no further plans to advance its ANGEL and MIRROR clinical development programs.

Autoimmune Product Candidate

Bioheart is pleased to announce the diversification of its product development pipeline into the treatment of autoimmune diseases. The Company plans to evaluate several autoimmune disease targets with its Adipocell(TM) therapy platform, the first of which will be Rheumatoid Arthritis (RA). The Company believes, for example, that if its Adipocell(TM) first generation, investigational research program into the treatment of RA achieves proof of efficacy, an advanced clinical development program could produce an approved cellular therapy that would have a profound impact on the debilitating effects of RA. RA is a chronic disease that causes pain, stiffness, swelling, and loss of function in the joints. It occurs when your immune system, the system that protects your body from outside harm, mistakenly starts attacking healthy tissue. This causes inflammation that leads to swelling in the joints making them progressively less mobile. If not managed properly, over time, RA can cause joint damage and can even result in permanent joint destruction. According to the Arthritis Foundation, RA affects approximately 1.3 million Americans, but unlike osteoarthritis, RA is not associated with factors such as aging, obesity, or injury. The Company believes that market approval could be achieved by 2018 for the treatment of RA.

Product Development Pipeline Summary

Based on the above information, Bioheart's Product Development Pipeline is summarized as follows:

View photo
.

"Myocell(TM), Myocell(TM) SDF-1, and Adipocell(TM) are unique product candidates that could have a profound impact on improving the lives of millions of people," said Mike Tomas, Bioheart's President and CEO. "Success comes from focus. The opportunities in regenerative medicine are endless but as an emerging company, we need to improve the odds of fulfilling our mission by knowing what is achievable and achieving it. We believe that the financial resources generated through our educational, animal health and personalized medicine products and services coupled with appropriate financing can bring these exciting product development candidates to market."

END quote of today's "vast" and "vague" typical IMO BHRT ole PR.

Hey, so how'd that ole MIRROR and ANGEL "stuff" work out? Boy, a LOT of PR about those- remember those PR's? I do.

Additional information regarding Bioheart's clinical development programs will be discussed at its upcoming February 4, 2015, 4:30 PM EST shareholder conference call and future SEC filings."

Where's that ole "appropriate financing"?? What exactly is "appropriate" financing? Kinda missing a few NUMBERS there maybe, like any ACTUAL NUMBERS or where this "appropriate financing" is going to come from?? Is there "inappropriate financing" too? What's the difference between them? I don't get it?

Sounds like a PR full of nothing concrete, TOTALLY lacking in a single financial explanation or detailed numbers of what this imaginary stuff will cost, vague wording as always like "we'll let you know at some future date" (you know, like TODAY THAT MIRROR AND ANGEL ARE SUNK AND CANCELLED) and no explanations of a single number on what even one of these pie in the sky programs will cost, several vague dates years out in the future- w/o a single timeline explaining how those dates or even interim target dates will be hit and achieved via what staff and what funding etc. A claim is made that CLI has shown supposed "positive outcomes" but WHERE ARE THEY PUBLISHED, what MEDICAL JOURNAL or anywhere are these supposed "positive outcomes" to be seen for peer review and presented in an actual SCIENTIFIC FORMAT past "shown positive results"- which is just someone saying so IMO. DATA, where's the published DATA then on CLI- in a credible medical journal or similar publication?

Man, what a classic PR if there ever was one IMO. Wow. I gotta print this one out and take a highlighter to it- to decipher all that's in it? It's so vast, so vague, jumps all over the map- with a bunch of vast market size "predictions" given by some group or whatever, then several programs now cancelled, but supposed newer ones, for which BHRT has little to no known experience or expertise are now being moved up as their latest "claims" while the other's were just dropped w/o explanation, etc?

OK, whatever. Great "PR" blah, blah to me. One for the history books- I'll put all those dates and estimates down and be looking for the updates, just like that classic MIRROR ole phase 3 and Angel. Remember Angel- how much it was used to hype the stock price? Remember that? Well, now it's cancelled and gone. How's that "work" exactly too? I'd love some more details on that one, another BHRT classic IMO.

http://finance.yahoo.com/news/bioheart-announces-phase-angel-trial-110823792.html

http://pipelinereview.com/index.php/2014030453581/DNA-RNA-and-Cells/Bioheart-Announces-Positive-6-Month-Data-From-Angel-Phase-I-Trial.html

http://www.marketwired.com/press-release/bioheart-receives-2-million-term-sheet-investment-offer-from-vitalmex-global-leader-otcbb-bhrt-1686526.htm

Oh, and they say their "animal program" or something? WHAT ANIMAL WHATEVER? WHERE is that in any SEC filing? Who of the 4 full time people is working on that? Last I checked Comella is in a lawsuit with the "animal thing"? See the case below, Comella is being sued by Stemlogix. Wasn't that Bioheart's and her's "animal thing"?? So how is that still on-going or whatever?

https://www.clerk-17th-flcourts.org/Clerkwebsite/BCCOC2/OdysseyPA/CaseSummary.aspx?CaseID=7155410&hidSearchType=party_case&DisplayCitation=no&CaseNumber=CACE13024037&SearchType=

I haven't seen a SEC filing discussing "animal products" or programs in any detail in I can't remember how long?

http://www.marketwired.com/press-release/bioheart-partnership-with-stemlogix-leads-first-us-combination-regenerative-medicine-1733056.htm

I don't think Comella is even listed anymore on the Stemlogix website- if that site is even operational anymore, from last time I checked?
So what exactly is Bioheart's "animal" whatever- where's the details on all that? More confusion IMO?

A Google search of "Stemlogix Florida" now brings up a Google+ page with "Vet Biologics" plastered all over it- the name Stemlogix not even in use anymore? Is this Bioheart I guess? Where does it say Bioheart on it?

Oh, it's got the Bioheart address listed as the contact info- so it looks like they moved from the old Stemlogix being run out of a residential home (Google used to show it as a home) to now a new name of "Vet Biologics" (every "Stemlogix" I clicked on now re-directs to this "Vet Biologics website??) and no longer Stemlogix- what SEC filing was that all explained in? Did I miss that one too or something?

The Florida Secretary of State still shows it as "Stemlogix" and at the address of "SWEETGUM TERRACE" - so what's this "Vet Biologics" now that is being done on a re-direct via any click on "Stemlogix"?? Makes no sense to me? Here is the Stemlogix LLC filing with Florida gov website:

http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=STEMLOGIX%20L100000617380&aggregateId=flal-l10000061738-8f1560a3-97a1-448b-b02f-17e79a596386&searchTerm=stemlogix&listNameOrder=STEMLOGIX%20L100000617380

"Vetbiologics" doesn't seem to come up as a business entity on the Florida Secretary of State site that I can find? And Stemlogix docs on that govt. maintained site show no name change to "Vetbiologics" or whatever? I'm confused I guess? Makes no sense to me?

Wow, heck of a vast and vague and scatter-shot ole PR IMO. I sure don't "get it"- especially how ole MIRROR and ANGEL just vanished now w/o any explanation?